Italia markets closed

Silence Therapeutics plc (SLN.L)

LSE - LSE Prezzo differito. Valuta in GBp.
Aggiungi a portafoglio
544,00-2,00 (-0,37%)
Alla chiusura: 4:35PM BST
Schermo intero
Chiusura precedente546,00
Aperto545,00
Denaro553,00 x 0
Lettera563,00 x 0
Min-Max giorno527,00 - 559,00
Intervallo di 52 settimane330,00 - 680,00
Volume112.627
Media Volume68.482
Capitalizzazione488,161M
Beta (5 anni mensile)1,19
Rapporto PE (ttm)N/D
EPS (ttm)-48,60
Prossima data utili12 ago 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development

    Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development 1 September 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of John Strafford, Ph.D., to the n

  • GlobeNewswire

    Silence Therapeutics to Participate in September Investor Conferences

    Silence Therapeutics to Participate in September Investor Conferences 25 August 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will present at two virtual investor conferences in September, details of which can be found below: Mo

  • GlobeNewswire

    Silence Therapeutics Reports Half-Year 2021 Results

    Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to host R&D Day in New York City on October 21, 2021 August 12, 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases